SCHEDULE 13G/A: Morgan Stanley Discloses 7.8% Stake in PROKIDNEY CORP. Through Latest SEC Filing

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have disclosed a 7.8% beneficial ownership stake in PROKIDNEY CORP. as of March 31, 2025, according to an amended Schedule 13G filing.

Summary

• Morgan Stanley and its wholly-owned subsidiary, Morgan Stanley Investment Management Inc., collectively reported beneficial ownership of 7.8% of PROKIDNEY CORP.'s Ordinary Shares.
• As of March 31, 2025, Morgan Stanley beneficially owned an aggregate of 10,058,924 Ordinary Shares.
• Morgan Stanley held shared voting power over 9,899,553 shares and shared dispositive power over 10,048,401 shares.
• Morgan Stanley Investment Management Inc. beneficially owned an aggregate of 10,043,784 Ordinary Shares, representing 7.8% of the class.
• Morgan Stanley Investment Management Inc. held shared voting power over 9,887,831 shares and shared dispositive power over 10,043,784 shares.
• The filing is an Amendment No. 4 to a Schedule 13G, indicating an update to previously reported beneficial ownership information.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of PROKIDNEY CORP.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. It does not contain positive or negative performance indicators or forward-looking statements that would influence sentiment.

Risks

• Intentional misstatements or omissions of fact in the filing constitute federal criminal violations.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing reflects a significant institutional investment firm's stake in a publicly traded company, which is a common occurrence in the financial markets. It does not provide broader industry trends but indicates continued institutional interest in PROKIDNEY CORP.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.
• Company Management: Informs management of a substantial shareholder, potentially impacting future engagement and strategic considerations.

Key Dates

Keywords

PROKIDNEY CORP., Morgan Stanley, Morgan Stanley Investment Management Inc., Schedule 13G, Beneficial Ownership, Ordinary Shares, SEC Filing, Institutional Ownership, Investment Management